Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET, SUGAR COATED
**Dosage and administration** Adults and Children 12 years of age and over: One Clarityn-D® 12Hour Repetabs tablet twice a day.
ORAL
Medical Information
**Indications and usage** Clarityn-D® 12Hour Repetabs is indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation. Clarityn-D® 12Hour Repetabs is recommended when both the antihistaminic properties of loratadine and the decongestant effect of pseudoephedrine sulfate are desired.
**Contraindications** Clarityn-D® 12Hour Repetabs are contraindicated in patients who have shown hypersensitivity or idiosyncrasy to their components, to adrenergic agents or to other drugs of similar chemical structure. Clarityn-D® 12Hour Repetabs are also contraindicated in patients receiving MAO inhibitor therapy or within 2 weeks of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.
R01BA52
pseudoephedrine, combinations
Manufacturer Information
BAYER (SOUTH EAST ASIA) PTE LTD
SAG Manufacturing SLU
Active Ingredients
Documents
Patient Information Leaflets
Clarityn-D 12 hour Repetabs PIL and PI.pdf
Approved: July 13, 2022